“Retirement Secret” Showed 995% Gain Last Time We Shared It

Central Banks Buying Gold in Record Numbers Most folks have completely missed the fact that the world's Central Banks have been quietly gobbling up as much gold as they can… Stacking it in their locked vaults on pallets in record numbers.

Find out why right here (and see what you can do to get in too with just a few dollars).

Joseph J. Sarret net worth and biography

Joseph Sarret Biography and Net Worth

CEO of CohBar

Joseph J. Sarret joined CohBar as Chief Executive Officer and Director in May 2021. From 2019 until 2021, Dr. Sarret worked as a consultant in the life science industry, focusing on business development and corporate development activities. From 2015 until 2019, he served as Chief Business Officer at Corium International, Inc. (formerly NASDAQ: CORI), a biopharmaceutical company developing and commercializing transdermal healthcare products. Prior to Corium, Dr. Sarret served in senior leadership roles at Solazyme, Inc. (formerly NASDAQ: SZYM) and Sevident, Inc. From 2005 to 2012, he held several executive management roles, most recently serving as Chief Business Officer at Codexis, Inc. (NASDAQ: CDXS), a publicly traded life sciences company developing novel enzymes for a variety of applications. Earlier in his career, Dr. Sarret worked as a practicing clinician focused on patients with human immunodeficiency virus and an attorney specializing in IP transactional work in the life sciences industry. He received a B.A. in human biology from Stanford University, an M.D. from the University of California, San Francisco School of Medicine and a J.D. from Stanford Law School.

How do I contact Joseph J. Sarret?: The corporate mailing address for Dr. Sarret and other CohBar executives is 1455 Adams Drive Suite 2050, Menlo Park CA, 94025. CohBar can also be reached via phone at (650) 446-7888 and via email at [email protected]. Learn More on Joseph J. Sarret's contact information.
Has Joseph J. Sarret been buying or selling shares of CohBar?: Joseph J. Sarret has not been actively trading shares of CohBar during the last ninety days. Most recently, on Wednesday, August 18th, Joseph J. Sarret bought 20,000 shares of CohBar stock. The stock was acquired at an average cost of $1.12 per share, with a total value of $22,400.00. Learn More on Joseph J. Sarret's trading history.
Who are CohBar's active insiders?: CohBar's insider roster includes Kenneth Cundy (Insider), Misha Petkevich (Director), and Joseph Sarret (CEO). Learn More on CohBar's active insiders.

Joseph J. Sarret Insider Trading History at CohBar

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
8/18/2021	Buy	20,000	$1.12	$22,400.00

Joseph J. Sarret Buying and Selling Activity at CohBar

CohBar Company Overview

CohBar, Inc., a clinical stage biotechnology company, develops mitochondria and peptides based therapeutics for the treatment of chronic and age-related diseases. It develops CB4211, a therapeutic that is in Phase 1a/1b clinical trial for the treatment of nonalcoholic steatohepatitis and obesity; and CB5138 Analogs, which is in preclinical study to treat idiopathic pulmonary fibrosis and other fibrotic diseases. CohBar, Inc. was incorporated in 2007 and is based in Menlo Park, California.

Today's Range

Now: $0.80

$0.80

50 Day Range

MA: $0.82

$0.76

$1.00

2 Week Range

Now: $0.80

$0.51

$6.90

Volume

7 shs

Average Volume

1,006 shs

Market Capitalization

$2.33 million

P/E Ratio

N/A

Dividend Yield